1-20 of 154
J Johnson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparison of the CXCR5-Antibody Drug Conjugate (ADC; VIP924) to a CD19-ADC and a CD79b-ADC in a Humanized Rec-1 Mantle Cell Lymphoma (MCL) Mouse Model

Tibor Schomber, Beatrix Stelte-Ludwig, Anne-Sophie Rebstock, Oliver v Ahsen, Amy J Johnson, Raquel Izumi, Ahmed Hamdy
Journal: Blood
Blood (2023) 142 (Supplement 1): 2809.
https://doi.org/10.1182/blood-2023-182185
Published: 2023
Journal Articles

Selectivity and Safety of VIP943: A Novel CD123-Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class

Beatrix Stelte-Ludwig, Tibor Schomber, Raquel Izumi, Harvey Wong, Melanie M Frigault, Anne-Sophie Rebstock, Sebastian Ludwig, Arushi Mithal, Amy J Johnson, Ahmed Hamdy
Journal: Blood
Blood (2023) 142 (Supplement 1): 1435.
https://doi.org/10.1182/blood-2023-182260
Published: 2023
Journal Articles

Targeting CDK9 in KMT2A-Rearranged Infant Leukemia: Evidence for Activity and Drug Synergy with Enitociclib

Ritul Sharma, Melanie M Frigault, Amy J Johnson, Raquel Izumi, Ahmed Hamdy, Joseph Birkett, Beatrix Stelte-Ludwig, Luke Maese, Norman J. Lacayo, Aru Narendran
Journal: Blood
Blood (2023) 142 (Supplement 1): 4293.
https://doi.org/10.1182/blood-2023-180567
Published: 2023
Journal Articles

Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

Son Tran, Ritul Sharma, Chunfen Zhang, Ranjan Maity, Amy J. Johnson, Melanie M. Frigault, Raquel Izumi, Ahmed Hamdy, Beatrix Stelte-Ludwig, Nizar J. Bahlis, Paola Neri, Aru Narendran
Journal: Blood
Blood (2022) 140 (Supplement 1): 10685–10686.
https://doi.org/10.1182/blood-2022-169917
Published: 2022
Journal Articles

Gamma' Fibrinogen Levels As a Biomarker of COVID-19 Severity

Lucy Z Kornblith, Bindhya Sadhanandhan, Sreepriya Arun, Rebecca Long, Alicia J Johnson, Jamie Noll, CN Ramchand, John K Olynyk, David H Farrell
Journal: Blood
Blood (2022) 140 (Supplement 1): 2749–2750.
https://doi.org/10.1182/blood-2022-162765
Published: 2022
Journal Articles

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

Hans C. Lee, Gregory P. Kaufman, Lei Feng, Astrid Murga, Ralph J. Johnson, Donna M. Weber, Sheeba K Thomas, Qaiser Bashir, Muzaffar H Qazilbash, Swaminathan P. Iyer, Krina Patel, Melody R. Becnel, Elisabet E. Manasanch, Robert Z. Orlowski
Journal: Blood
Blood (2022) 140 (Supplement 1): 4428–4430.
https://doi.org/10.1182/blood-2022-167555
Published: 2022
Journal Articles

VIP943 Is a Novel CD123 Antibody Drug Conjugate with in Vitro and In Vivo Efficacy in Acute Myeloid Leukemia (AML) Models

Beatrix Stelte-Ludwig, George Clemens, Tibor Schomber, Melanie M. Frigault, Amy J. Johnson, Hans-Georg Lerchen, Raquel Izumi, Ahmed Hamdy
Journal: Blood
Blood (2022) 140 (Supplement 1): 5955–5956.
https://doi.org/10.1182/blood-2022-167556
Published: 2022
Journal Articles

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Mazyar Shadman, Anthony R. Mato, Connie Lee Batlevi, Ian W. Flinn, Martin Gutierrez, Marc Uemura, Don A. Stevens, Daniel Morillo, John C. Byrd, Melanie M. Frigault, George Clemens, Xin Huang, Raquel Izumi, Harvey Wong, Renee Breed, Hermes Garban, Amy J. Johnson, Beatrix Stelte-Ludwig, Arushi Mithal, Joseph Birkett, Ahmed Hamdy, Kerry A. Rogers
Journal: Blood
Blood (2022) 140 (Supplement 1): 9454–9456.
https://doi.org/10.1182/blood-2022-167651
Published: 2022
Journal Articles

VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia

Steven Sher, Larry Beaver, Katie Williams, Shelley Orwick, Brandi R. Walker, Charles Thomas Gregory, Matthew Purcell, Alexander Pan, Pearlly S. Yan, Amy J. Johnson, Melanie M. Frigault, Joy M. Greer, Ahmed Hamdy, Raquel Izumi, Stuart Hwang, James S. Blachly, John C. Byrd, Rosa Lapalombella
Journal: Blood
Blood (2021) 138 (Supplement 1): 270.
https://doi.org/10.1182/blood-2021-153812
Published: 2021
Journal Articles

VIP152, a Selective CDK9 Inhibitor, Induces Complete Regression in a High-Grade B-Cell Lymphoma (HGBL) Model and Depletion of Short-Lived Oncogenic Driver Transcripts, MYC and MCL1, with a Once Weekly Schedule

Melanie M. Frigault, Harvey Wong, Hermes Garban, Joy M. Greer, Stuart Hwang, Raquel Izumi, Amy J. Johnson, Beatrix Stelte-Ludwig, Ahmed Hamdy
Journal: Blood
Blood (2021) 138 (Supplement 1): 1192.
https://doi.org/10.1182/blood-2021-150917
Published: 2021
Journal Articles

Nutrition As a Predictor of Microbiome Injury in Allo-HCT

Anqi Dai, Peter A. Adintori, Melissa D Docampo, Corrado Zuanelli Brambilla, Marissa L. Buchan, Antonio L.C. Gomes, Marina D Burgos da Silva, Kate A Markey, Sean M Devlin, Annelie Clurman, John B Slingerland, Abigail J. Johnson, Dan Knights, Robert R. Jenq, Sergio A Giralt, Miguel-Angel Perales, Marcel van den Brink, Jonas Schluter, Jonathan U Peled
Journal: Blood
Blood (2021) 138 (Supplement 1): 746.
https://doi.org/10.1182/blood-2021-150762
Published: 2021
Journal Articles

Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma

Clinical Trials & Observations
Paolo Strati, Preetesh Jain, Ralph J. Johnson, Sheryl Forbes, Lei Feng, Felipe Samaniego, Maria A. Rodriguez, Luis E. Fayad, Fredrick Hagemeister, Jason Westin, Michael Wang, Sattva S. Neelapu, Loretta J. Nastoupil, Nathan H. Fowler
Journal: Blood
Blood (2021) 137 (8): 1124–1129.
https://doi.org/10.1182/blood.2020007994
Published: 2021
Includes: Supplemental data
Journal Articles

Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM)

Sheeba K. Thomas, MD, Jatin J. Shah, MD, Armando Morin, M.A., Ashley N. Morphey, M.S.N., Hans C. Lee, MD, Elisabet E. Manasanch, MD, Krina K. Patel, MD, Gregory P. Kaufman, MD, Swami P. Iyer, MD, Lei Feng, MS, Behrang Amini, MD PhD, Muzaffar H. Qazilbash, MD, Qaiser Bashir, MD, Neeraj Saini, MD, Samer A. Srour, MD MS, Ralph J. Johnson, PhD, Brandon N. Crumpton, Mildred D. Stafford, Donna M. Weber, MD, Robert Z. Orlowski, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-139934
Published: 2020
Journal Articles

Indirect Treatment Comparison of CC-486 Versus Azacitidine (AZA) As Maintenance Therapy for Acute Myeloid Leukemia (AML)

Ashley Tabah, David Huggar, Si-Tien Wang, Scott J. Johnson, Ronda Copher, PhD, Thomas O'Connell, Thomas W. Leblanc
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-136752
Published: 2020
Journal Articles

Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia

Eli Muchtar, MD, Amber Koehler, PA-C, Michael J Johnson, Kari G Rabe, Wei Ding, MD PhD, Timothy G. Call, MD, Jose F. Leis, MD PhD, Saad S. Kenderian, MB, ChB, Suzanne R. Hayman, MD, Yucai Wang, MDPhD, Paul J. Hampel, MD, Mathew Holets, Heather C Darby, Susan L. Slager, PhD, Neil E. Kay, MD, Jennifer A Whitaker, Myron Levin, Richard Kennedy, Adriana Weinberg, Sameer A. Parikh, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 49–50.
https://doi.org/10.1182/blood-2020-140338
Published: 2020
Journal Articles

The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells

Carsten Riether, PhD, Tanja Chiorazzo, PhD, Amy J. Johnson, PhD, Christina Diane Drenberg, PhD, Khaja Waheeduddin Syed, BPharm, MS, Mahan Moshir, MSc, Anna Hultberg, PhD, Nicolas Leupin, Hans De Haard, Adrian F Ochsenbein, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3918.
https://doi.org/10.1182/blood-2019-127464
Published: 2019
Journal Articles

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Paolo Strati, MD, Ralph J. Johnson, PhD, Sheryl G Forbes, Loretta J. Nastoupil, MD MSc, Felipe Samaniego, MD, Eric Davis, MD, Michael R Green, PhD, Luis Fayad, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Michael L. Wang, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1533.
https://doi.org/10.1182/blood-2019-129311
Published: 2019
Journal Articles

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

Rosalie M. Sterner, Reona Sakemura, Michelle J. Cox, Nan Yang, Roman H. Khadka, Cynthia L. Forsman, Michael J. Hansen, Fang Jin, Katayoun Ayasoufi, Mehrdad Hefazi, Kendall J. Schick, Denise K. Walters, Omar Ahmed, Dale Chappell, Tarek Sahmoud, Cameron Durrant, Wendy K. Nevala, Mrinal M. Patnaik, Larry R. Pease, Karen E. Hedin, Neil E. Kay, Aaron J. Johnson, Saad S. Kenderian
Journal: Blood
Blood (2019) 133 (7): 697–709.
https://doi.org/10.1182/blood-2018-10-881722
Published: 2019
Includes: Supplemental data
Journal Articles

JNJ-64457107, a CD40 Agonist, Induces Cell Death in BCL6 hi IRF4 neg GCB Subtype of DLBCL

Joshua J. Rusbuldt, MA, Andressa A. Smith, PhD, Sriram Balasubramanian, Gary Borzillo, PhD, Amy J. Johnson, PhD, Diana Alvarez Arias, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1674.
https://doi.org/10.1182/blood-2018-99-114622
Published: 2018
Journal Articles

Multiplex Human T Cell Engineering without Double-Strand Break Induction Using the Cas9 Base Editor System

Beau Webber, PhD, Cara-lin Lonetree, MS, Miechaleen Diers, Walker S Lahr, Kluesner Mitchell, Matthew J Johnson, PhD, Branden S Moriarity, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3495.
https://doi.org/10.1182/blood-2018-99-120372
Published: 2018